share_log

Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Chardan Capital维持对Seres Therapeutics的买入,将目标股价下调至8美元
Moomoo 24/7 ·  03/06 07:38

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from $10 to $8.

Chardan Capital分析师Keay Nakae维持Seres Therapeutics(纳斯达克股票代码:MCRB)的买入并将目标股价从10美元下调至8美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发